Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025389 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00025389 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 8 participants.
The verdict
NCT00025389, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy before surgery may may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is to see if bevacizumab, paclitaxel, and carboplatin given before surgery work in treating patients who have stage IB, stage II, or stage IIIA non-small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- BIOLOGICAL bevacizumab
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2001-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025389
The ClinicalTrials.gov registry entry for NCT00025389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00025389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025389 about?
NCT00025389 is a clinical study titled "Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to ...
What is the current status of trial NCT00025389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2001-11. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00025389?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), bevacizumab (BIOLOGICAL), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00025389?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.